ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer’s disease (AD), amyotrophic lateral sclerosis…

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral…

Promis Neurosciences (NASDAQ:PMN) Upgraded to “Moderate Buy” at Leede Financial

Promis Neurosciences (NASDAQ:PMN – Get Free Report) was upgraded by research analysts at Leede Financial to a “moderate buy” rating in a research report issued on Monday,Zacks.com reports. Leede Financial also issued estimates for Promis Neurosciences’ FY2029 earnings at $0.88 EPS. Several other research firms have also recently issued reports on PMN. Guggenheim reiterated a […]

Still undervalued? ProMIS Neurosciences keeps $9.50 target price at Leede

The U.S. FDA has granted Fast Track designation to ProMIS Neurosciences’ (ProMIS Neurosciences Stock Quote, Chart, News, Analysts, Financials NASDAQ:PMN) Alzheimer’s candidate PMN310, sending the company’s shares up more than 150% on July 21. The stock closed at US$1.12, up from US$0.44, after peaking at US$1.38 earlier in the session. Leede Financial analyst Douglas Loe […] Source

Study finds eating one egg per week may reduce risk of Alzheimer's disease - Islamabad Post

Eggs have been a part of the human diet since before modern humans existed. While they are rich in nutrients, affordable, and widely available, their role in health has long been debated. A recent study published in The Journal of Nutrition may help restore eggs’ positive reputation. Researchers found that consuming one egg per week was linked to a 47% lower risk of developing Alzheimer’s disease compared to eating eggs less than once a month, r…